Atara Biotherapeutics, Inc.
ATRA$39M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaTHOUSAND OAKS38 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
7wMarket Overview
Stock performance and key metrics
ATRA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-induced Lymphomas
EBV-specific T cells (EBV-CTLs)
EBV-induced Lymphomas
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply